Friday, January 24, 2020

Epizyme Inc on Thursday priced its treatment for a ultra rare, slow growing type of cancer that affects soft tissue at $15,500 per month after getting an approval from the U.S. Food and Drug Administration.


from Reuters: Health News https://ift.tt/2TTIJfs

Related Posts:

  • LATEST HEALTH NEWSDelivering blood to our brains is one of those automatic internal processes that most of us seldom consider, although it is essential for life and cognition from Health https://ift.tt/2Lriyoq … Read More
  • LATEST HEALTH NEWSOncoStem diagnoses chances of breast cancer relapse via data from Health https://ift.tt/2M9GTEF … Read More
  • LATEST HEALTH NEWSUsing nanoparticles to get drugs directly into a tumour is a growing area of cancer research from Health https://ift.tt/2Mnt0Tg … Read More
  • LATEST HEALTH NEWSIndia's childhood stunting rate is one of the world's worst, surpassed only by Bangladesh (73%) and Afghanistan (67%) from Health https://ift.tt/2KVgmVY … Read More
  • LATEST HEALTH NEWS(Reuters Health) - When people take daily pills to minimize their chances of getting HIV, they are also more likely to get routine care like flu shots and recommended screenings for common health problems, a U.S. study sugges… Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner